Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Birtcher Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Previously announced negotiations for a private placement of $7 mil. from an institutional investor are in jeopardy. The financially troubled Irvine, California-based company announced Nov. 3 that its board had agreed to provide information about the company to an unnamed third party who had expressed interest in acquiring the firm. The third party suitor's identity and proposed terms remain undisclosed due to "the preliminary nature of the inquiry." Birtcher says that the institutional investor has informed the company that "it interprets Birtcher's actions as an election not to proceed with the proposed private placement," and will pursue legal means to recover fees and expenses stemming from the matter. Birtcher had made public its negotiations for the private placement, consisting of $7 mil. in convertible preferred stock, at the same time it announced its 1993 losses of $20.6 mil. ("The Gray Sheet" Sept. 26, p. 10). Birtcher says it "does not believe its actions violate the terms of its agreement with the institutional investor and has informed the investor that it wishes to continue negotiation with respect to the proposed private placement."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT003018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel